A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) (CASCA)
A Phase 2, Open-label, Proof-of-Concept Study to Investigate the Efficacy, Safety, and Tolerability of TAK-411 in Adult Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (The CASCA Study)
Sponsor: Takeda
This observational or N/A phase trial investigates Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and is currently actively recruiting participants. Takeda leads this study, which shows 10 recorded versions since 2025 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
Phase: PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
▶ Show 5 earlier versions
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2025 — May 2025 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
CIDP is an autoimmune disease. This means that the body's germ fighting (immune) system attacks itself. In CIDP, the immune system attacks the protective covering around the nerves called myelin. Over time, these nerves lose their ability to send signals to the muscles in the body. This leads to muscle weakness and loss of sensation in arms and legs among other symptoms. Participants with CIDP can be treated with a protein called immunoglobulin (or IG). TAK-411 is a special type of immune globulin G (hsIgG) that has been chemically changed. It is made from IG that comes from human plasma. This study will test if TAK-411 can decrease inflammation and improve symptoms of CIDP. The main aim of this study is to check how TAK-411 affects the physical functioning of adults with CIDP when compared with results of the placebo group of a historical trial. Participants may be treated with TAK-411 for up to 1 year (51 weeks) and will be followed up for 3 weeks after last dose. During the study, participants may visit their study clinic up to approximately 21 times.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .